Late-onset neurologic disease in glutaryl-CoA dehydrogenase deficiency

Neurology. 2005 Jun 28;64(12):2142-4. doi: 10.1212/01.WNL.0000167428.12417.B2.

Abstract

Neurologic disease in glutaryl-CoA dehydrogenase (GCDH) deficiency usually presents with acute encephalopathic crises before 2 years of age. The authors report two previously asymptomatic patients with macrocephaly presenting with progressive neurologic deterioration and a severe leukoencephalopathy during adolescence or adulthood.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age of Onset
  • Aged
  • Atrophy / enzymology
  • Atrophy / genetics
  • Atrophy / physiopathology
  • Brain Diseases, Metabolic, Inborn / enzymology*
  • Brain Diseases, Metabolic, Inborn / genetics
  • Brain Diseases, Metabolic, Inborn / physiopathology*
  • Carnitine / therapeutic use
  • Cerebral Cortex / enzymology*
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology*
  • Cognition Disorders / enzymology
  • Cognition Disorders / genetics
  • Cognition Disorders / physiopathology
  • DNA Mutational Analysis
  • Disease Progression
  • Food, Formulated
  • Glutaryl-CoA Dehydrogenase / deficiency*
  • Humans
  • Lateral Ventricles / pathology
  • Magnetic Resonance Imaging
  • Male
  • Movement Disorders / enzymology
  • Movement Disorders / genetics
  • Movement Disorders / physiopathology
  • Mutation / genetics
  • Nerve Fibers, Myelinated / pathology
  • Treatment Outcome

Substances

  • Glutaryl-CoA Dehydrogenase
  • Carnitine